Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHERLOC: MM-121 (seribantumab) plus docetaxel vs docetaxel in heregulin-positive metastatic NSCLC
2014-003673-42Phase 2Terminated
- Sponsor
- Merrimack Pharmaceuticals
- Start
- Sep 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of seribantumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merrimack Pharmaceuticals. Primary endpoint: Progression-Free Survival. Started Sep 2015; status: terminated.
02
Drugs
seribantumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2014-003673-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003673-42.